Thyroid Cancer clinical trials in Illinois

7 actively recruiting thyroid cancer trials at 49 sites across Illinois.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 3 Recruiting Network

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

This phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid cancer that does not respond to treatment (refractory) and which expresses a BR…

Sponsor: ECOG-ACRIN Cancer Research Group

NCT ID: NCT06475989

Sites in Illinois:

OSF Saint Anthony's Health Center — Alton, Illinois
Saint Mary's Hospital — Centralia, Illinois
Northwestern University — Chicago, Illinois
University of Illinois — Chicago, Illinois
Northwestern Medicine Cancer Center Kishwaukee — DeKalb, Illinois

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.

NCT ID: NCT03093116

Sites in Illinois:

University of Chicago — Chicago, Illinois
Local Institution - 2142 — Peoria, Illinois

View on ClinicalTrials.gov →

Phase 2 Recruiting Academic/Other

XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer

This phase II trial tests how well XL092 works for the treatment of patients with differentiated thyroid cancer that has not responded to previous treatment with radioiodine (radioiodine refractory) and that has spread to nearby tissue or …

Sponsor: Northwestern University

NCT ID: NCT06959641

Sites in Illinois:

Northwestern University — Chicago, Illinois

View on ClinicalTrials.gov →

Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT05334069

Sites in Illinois:

OSF Saint Anthony's Health Center — Alton, Illinois
Rush-Copley Medical Center — Aurora, Illinois
Advocate Outpatient Center - Aurora — Aurora, Illinois
Advocate Good Shepherd Hospital — Barrington, Illinois
Carle BroMenn Outpatient Center — Bloomington, Illinois

View on ClinicalTrials.gov →

NA Recruiting Network

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.

Sponsor: Eastern Cooperative Oncology Group

NCT ID: NCT05108298

Sites in Illinois:

Saint Anthony's Health — Alton, Illinois
Rush - Copley Medical Center — Aurora, Illinois
Bromenn Lifecare Center — Bloomington, Illinois
Illinois CancerCare-Bloomington — Bloomington, Illinois
Illinois CancerCare-Canton — Canton, Illinois

View on ClinicalTrials.gov →

Recruiting Academic/Other

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…

Sponsor: University of Nebraska

NCT ID: NCT02012699

Sites in Illinois:

Rush-Copley Cancer Care Center — Aurora, Illinois
Rush-Copley Healthcare Center — Yorkville, Illinois

View on ClinicalTrials.gov →

Recruiting Industry

DESTINY-PANTUMOUR04

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have n…

Sponsor: AstraZeneca

NCT ID: NCT07124000

Sites in Illinois:

Research Site — O'Fallon, Illinois

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20